Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca Sells 11,699 Shares

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the sale, the executive vice president directly owned 110,167 shares in the company, valued at $14,501,282.21. The trade was a 9.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $133.10 on Thursday. The business has a fifty day simple moving average of $124.94 and a 200 day simple moving average of $119.64. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $328.38 billion, a price-to-earnings ratio of 106.48, a PEG ratio of 5.62 and a beta of 0.19. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The firm had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period last year, the business earned $2.13 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Institutional Investors Weigh In On Merck & Co., Inc.

Several large investors have recently made changes to their positions in MRK. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. during the 4th quarter valued at about $25,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the fourth quarter worth about $26,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. during the fourth quarter worth about $26,000. Graney & King LLC grew its stake in Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after buying an additional 200 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth approximately $31,000. Institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst sentiment improved: Daiwa Securities upgraded Merck to “outperform” and set a $143 price target, while Argus raised its target to $145 and maintained a “buy” rating. These targets imply additional upside from recent trading levels. Daiwa Securities upgrade
• Positive Sentiment: RSV expansion opportunity: The FDA and European Medicines Agency accepted supplemental applications for broader use of ENFLONSIA to prevent RSV in vulnerable young children. The regulatory reviews could expand Merck’s growth beyond oncology and help diversify the portfolio ahead of Keytruda’s future patent expirations. Merck RSV regulatory review article
• Positive Sentiment: Estimates edged higher: Erste Group raised its FY2026 earnings forecast for Merck to $2.75 per share from $2.70, broadly aligning with the $2.76 consensus estimate. The company also recently exceeded quarterly revenue and adjusted earnings expectations, reporting $16.61 billion in revenue.
• Positive Sentiment: Core business remains solid: Keytruda, oncology and animal health supported quarterly growth, while the company continues investing in its pipeline. Merck also declared its regular $0.85 quarterly dividend, equivalent to a $3.40 annualized payout.
• Neutral Sentiment: Vaccine-policy uncertainty: Reports that the administration may seek to split the MMR vaccine into separate shots could create headlines around the broader vaccine market, but experts say the proposal lacks scientific support and is unlikely to advance. MMR vaccine policy article
• Negative Sentiment: Repeated insider selling: EVP Richard R. Deluca sold roughly 45,000 shares across transactions from August 6 through August 12 for approximately $6.7 million. Although he retained a substantial position, the sales may weigh modestly on sentiment.
• Negative Sentiment: Longer-term risks persist: Analysts continue to flag falling estimates, a high valuation and upcoming patent expirations, particularly the eventual loss of Keytruda exclusivity. These issues could limit upside unless Merck’s pipeline and newer products offset the expected revenue pressure.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MRK. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Wells Fargo & Company raised their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Guggenheim upped their price objective on Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $135.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.